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Purpose: This study investigated the influence of angiotensin-1 converting enzyme (ACE) insertion-
deletion (ID) gene polymorphism on the treatment responses of type 2 diabetic subjects at varying 
stages of nephropathy to ACE inhibitors (ACEI) with regard to blood pressure (MAP) and renal response 
(GFR). 
Methods: The pharmacological effect of ACE inhibition on mean arterial pressure (MAP) and glomerular 
filtration rate (GFR) were observed among a total of 62 subjects for a short-term duration of 15 months. 
MAP and GFR were calculated by standard mathematical formulae while the ACE ID genotype was 
determined using triple primer PCR. The general linear model repeated measures were applied to study 
the modulation of ACE inhibition on these parameters.  
 Results: ACE ID genotyping of the 62 subjects showed that 19 (30.6 %) subjects had the II genotype, 
while 35 (56.4 %) subjects showed ID genotype and 8 (12.9 %) subjects had the DD genotype. 
Significant mean MAP reduction (p < 0.05) and null mean GFR changes (p > 0.05) from baseline values 
were observed among the subjects following antihypertensive treatment. However, when stratified 
according to ACE genotypes, no significant mean MAP and GFR changes were observed between 
genotypes following antihypertensive treatment (p > 0.05).  
Conclusion: ACE ID gene polymorphism does not determine the treatment efficacy of ACE inhibitors in 
the Malaysian population.  
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INTRODUCTION 
 
Many trial-proven strategies have been 
developed in preventing and delaying the 
progression of nephropathy in patients with 
diabetes. Maintenance of tight blood glucose 
and blood pressure controls, encouraging 
weight reduction and cessation of smoking, 
treating dyslipidaemia, restricting intake of 
protein diet, prescribing acute high or chronic 
low doses of erythropoietin and early 
identification and referral of patients with 
potential risk for developing end-stage renal 
failure are some of the diabetic nephropathy 
management strategies being practiced in 
primary health care settings for subjects at 
risk for developing diabetic nephropathy [1-2]. 
In addition, novel therapies including 
sulodexide, a glycosaminoglycan, 
pyridoxamine, an advanced glycation end 
product inhibitor, ruboxistaurin, a protein 
kinase C inhibitor and aliskiren, a renin 
inhibitor are promising in retarding disease 
progression of diabetic nephropathy both in 
animal models and small clinical studies [3]. 
 
Antihypertensive treatment (AHT), particularly 
the use of ACE inhibitors (ACEI), have been 
reported to show beneficial reno-protective 
effects in patients with diabetic and non-
diabetic nephropathy [4]. ACEIs execute 
hypotensive effects by decreasing the 
formation of a potent vasoconstrictor, 
angiotensin-II and by decreasing the 
degradation of the potent vasodilator, 
bradykinin while affecting glomerular 
haemodynamics by decreasing the 
glomerular capillary pressure. They also have 
an antiproteinuric effect superior to other 
AHTs [5].  
 
The II, ID and DD genotypes resulting from 
the polymorphic site of the ACE gene have 
been shown to have low, intermediate and 
high plasma expression, respectively. With 
that, the II genotype has been thought to 
confer protective benefits while DD genotype, 
is believed to confer deleterious effects on 
various disease pathogenetic mechanism 
particularly, diabetic nephropathy [6]. In 
addition, characterization of the ACE ID gene 
polymorphism has also been suggested for 
decision making regarding antihypertensive 
treatment regimens [7]. Hence, we 
investigated the role of ACE ID gene 
polymorphism in Malaysian diabetic 
nephropathic subjects in determining the 
effect of ACE inhibitors on mean arterial 
pressure (MAP) and glomerular filtration rate 
(GFR) in a short-term observational 
retrospective study. Additionally, we have 
also assessed the concomitant use of 
additional antihypertensive drugs to ACEI on 
the changes of mean MAP and GFR over 






Enrolment of subjects was conducted at the 
outpatient diabetes/nephrology clinic at the 
University of Malaya Medical Center 
(UMMC), Kuala Lumpur. Approval from the 
Medical Ethics Committee (UMMC) and 
informed consent from all recruited subjects 
were obtained. A total of 256 patients with 
varying stages of nephropathy were reviewed 
for the study. Following a thorough review of 
the medical records of these subjects, only a 
total of 62 subjects with type 2 diabetes 
mellitus (T2DM) and with a mean age (±SD) 
of 60.5 ± 8.4  (male: 38.7 %; female: 61.2 %) 
were selected for this retrospective 
observational study. Among these, 37 
subjects were also on one or two 
antihypertensive drugs in addition to ACEI. 
They had been on ACEIs consecutively for 
over 15 months with complete medical 
records from 2001 to 2007. All the diabetic 
patients included were hypertensive (BP > 
140/90 mmHg) and with varying degrees of 
kidney damage (ranging from stages I – III) 




Mean arterial pressure (MAP) was 
approximated by the equation, {2/3 * diastolic 
blood pressure (DBP)} + {1/3 * systolic blood 
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pressure (SBP)}. The ratio of total 
haemoglobin (Hb) to HbA1C concentration 
expressed by glycosylated hemoglobin 
(HbA1c) concentration in percentage, 
determined by cyanide-free colorimetric and 
latex agglutination method, respectively, was 
computed [9]. The glomerular filtration rate 
(GFR) was estimated by Cockcroft-Gault (C-
G) equation [10] as in Eq 1.  
 
GFR ml/min = {(140 - age) x weight (kg)} / {72 x 
serum creatinine (mg/dl)} ……………….……... (1). 
 
ACE ID genotyping 
 
Highly purified and concentrated genomic 
deoxyribonucleic acid (DNA) was isolated 
using the Wizard
R
 Genomic DNA purification 
kit (Promega, Madison) based on a series of 
lysis, precipitation and desalting procedures. 
The DNA was then subjected to triple primer 
polymerase chain reaction (PCR) 
amplification of the insertion/deletion (I/D) 
polymorphic site of the ACE gene as 
previously described [11]. Briefly, PCR was 
performed in a final volume of 25µl containing 
10mM Tris-HCl (pH 8.8), 50mM KCl, 0.8% 
Nonidet P40, 1.5mM MgCl2, 0.2mM dNTPs, 
20pmol of each primer (Forward: 5’-CCC 
ATC CTT TCT CCC ATT TCT C-3’, Nested: 
5’-GGT TTC ACC GTT TTA GCC GGG A-3’ 
and Reverse: 5’-CCA TGC CCA TAA CAG 
GTC TTC A-3’ primers, 1U Taq DNA 
Polymerase (Fermentas, Lithuania), and 
~100ng of genomic DNA. The optimized PCR 
run includes an initial denaturation at 94 
o
C 
for 3 min, followed by 30 cycles of 
denaturation at 94 
o
C for 30 s, annealing at 
64
 o
C for 30 s, and extension at 72
 o
C for 30 
s, and a final extension at 72 
o
C for 7 min in 
an Eppendorf Master Thermal Cycler 
(Eppendorf, Hamburg). Subsequently, 
following agarose gel (1.5 %) electrophoresis, 
ACE I/D genotyping was determined based 
on the discriminating band size pattern where 
band sizes of approximately 500 bp and 260 
bp designated the II genotype, while band 
sizes of approximately 500 bp, 260 bp and 
210 bp designated the ID genotype and a 
single band with a size of approximately 210 
bp indicates the DD genotype.  
ACE inhibitors (ACEI) observational 
retrospective study 
 
For the retrospective study, blood pressure 
readings were recorded from the subject’s 
respective medical records at 3 monthly 
intervals. Subsequently, the MAP was 
estimated thus, showing a total of 6 readings 
for the period under study. C-G equations-
based GFR measures were estimated as 
well. Zero (0) month is the onset point of drug 
administration, and therefore, considered as 
the baseline value.  
 
Statistical analysis  
 
Statistical Package for Social Sciences 
version 14.0 (Chicago, Illinois) was used to 
perform statistical analysis. Paired samples 
Students t-test was used to compare the 
means of HbA1c level between baseline and 
at month 15. Parametric one-way ANOVA 
procedure was used to test the mean MAP 
and GFR differences between the subgroups: 
(a) ACE genotype subgroups – II : ID : DD, 
and (b) Pharmacologic therapy subgroup – 
ACEI : ACEI + one AHT : ACEI + two AHT , 
at baseline. Post-hoc analysis was carried 
out using the Tukey post-hoc test as equal 
variances were assumed. The general linear 
model (GLM) repeated measures were 
applied to study the effects of ACE inhibitors 
on MAP and GFR over the period. Mauchly’s 
sphericity test was used to assess the 
assumption of sphericity, while the 
Bonferonni procedure was used to perform 
pairwise comparison between the groups of 





ACE ID genotyping and clinical 
characteristics  
 
Typical gel presentation showing the isolated 
DNA and PCR amplicons banding pattern 
based ACE ID genotyping are shown in 
Figures 1 and 2, respectively. Clinical  
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Figure 2: Typical ACE ID genotyping results by triple primer PCR. (Lane M: 50 bp DNA       
ladder; lanes 1-10: PCR product of samples in duplicate and its corresponding genotypes) 
 
 
Table 1: Clinical characteristics (mean ± SD) of 
subjects at baseline and endpoint of the study 
 
Parameter Baseline End-point 










HbA1c (%) 9.3±2.2 8.3±1.8* 
ACE ID genotype (n) 19:35:8 (II:ID:DD) 
Antihypertensive  
treatment (n)  
 
ACEI (only) 25 (II=8; ID=11; DD=6) 
+ 1 agent 25 (II=7; ID=17; DD=1) 
+ 2 agents 12 (II=4; ID=7; DD=1) 
MAP = mean arterial pressure; GFR = glomerular 
filtration rate; *Paired t-test, HbA1c levels at 15 months 
was significantly lower than the baseline value (p<0.01).  
 
characteristics of the subjects at both 
baseline and end-point are shown in Table 1.  
Table 1 indicates that homozygous insertion 
(II) alleles were found in 19 (30.6 %) patients 
while heterozygous insertion-deletion (ID) 
alleles and homozygous deletion alleles (DD) 
were found in 35 (56.5 %) and 8 patients 
(12.9 %), respectively. In terms of the 
antihypertensive therapy (AHT) regimens that 
had been administered to these subjects, 
40.3 % of the patients were on ACE inhibitors 
alone while 40.3% and 19.4% were on one 
and two additional antihypertensive agents, 
respectively (Table 1). The commonly used 
ACEI drugs include perindopril, lisinopril, 
enalapril and captopril, in that order. The 
types of drugs used in combination with ACE 
inhibitors were dihydropyridine calcium-
channel blockers (CCBs) including 
amlodipine, nifedipine and felodipine, as well 
as diuretics - thiazide and furosemide.  
 
Responses of MAP and GFR to 
antihypertensive treatment  
 
The p value for Mauchly test for all 
parameters tested was more than 0.05, 
hence  the  assumption  of  sphericity was 
met  (p > 0.05).  As expected,  test  of  within-  
  M       1       2      3      4      5       6      7      8       9       10     11      
10 kb 
1         2          3          4         5         6         7         8         9       10       M     
DD     DD      II          II        ID        ID        ID        ID        II        II 
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Table 2:  MAP and GFR responses to antihypertensive treatment over the duration of treatment 
  
Duration (months) Clinical parameter 
(mean±SEM) 0 3 6 9 12 15 
MAP (mmHg) 104.7±1.5 103.7±1.7 105.2±1.5 104.1±1.9 100.9±1.7 97.6±1.5 
GFR (ml/min) 69.8±3.5 70.7±3.7 71.3±3.4 69.8±3.9 70.4±4.0 69.2±3.5 
 
subjects effects showed a significant 
difference in the changes of mean MAP (p = 
0.001, Observed power, 95.6 %) but not in 
mean GFR (p = 0.963) over 15 months (see 
Table 2). Using the Bonferonni pairwise 
comparison, we found that there was a 
significant difference in mean MAP measures 
between months 1, 3, 6 and 15. 
 
Influence of combining other additional 
antihypertensive agents with ACEI on 
MAP and GFR  
 
Assessment of the influence of combining 
other AHTs with ACEI on mean MAP and 
GFR over time is shown in Figure 3. At 
baseline, the mean MAP of the subgroup on 
ACEI with 2 additional antihypertensive drugs 
was significantly higher compared to those on 
ACEI alone (p = 0.03; Tukey post hoc test, p 
< 0.05). However, the mean baseline GFR 
between the subgroups (p = 0.929) was not 
significantly different. Based on the test of 
between-subjects effects, it was observed 
that there was a significant mean MAP 
change between subgroups (p < 0.00; 
Observed power, 99 %) but not in the mean 
GFR (p = 0.575) over time (Figure 3). 
Bonferonni pairwise comparisons showed a 
significantly lower mean MAP at 15 months 
from the baseline mean MAP among those 
on ACE inhibitors with two additional 
antihypertensive agents. 
 
Impact of ACE ID gene polymorphism on 
MAP and GFR and antihypertensive 
treatment outcomes 
 
Mean MAP and GFR were similar when 
stratified according to ACE ID genotypes at 
baseline (p = 0.537 and 0.571, respectively). 
Further test of between-subjects effects 
between mean MAP and GFR and ACE ID 
genotypes gave p values of 0.634 and 0.372, 
respectively, indicating that there were no 
significant mean MAP and GFR changes 
between the subgroups over time (Figure 4). 
 
 
Figure 3: Mean MAP and GFR combined ACEI 
and other AHTs over the duration of treatment. 
(Key: ○ = ACEI; □ = ACEI + one AHT; ∆ = ACEI + 
two AHT). 
 
    
Figure 4: Mean MAP and GFR according to ACE 
genotype over the duration of treatment  
(Key: ○ = II; □ = ID; ∆ = DD) 
 
Influence of ACE ID gene polymorphism 
on MAP and GFR for ACEI alone 
 
Changes in the mean MAP and GFR were 
also evaluated in subjects who were 
exclusively treated with ACEI (n = 25; II = 8, 
ID = 11, DD = 6). And again, no significant 
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changes in both the MAP (p > 0.05) and GFR 
(p > 0.05) between subgroups were observed 




The aim of this retrospective study was to 
observe the influence of ACE ID gene 
polymorphism on the responses of MAP and 
GFR to ACE inhibitors over period of 15 
months. The effects of other antihypertensive 
agents administered concurrently with ACEI 
on changes of MAP and GFR over this period 
were also assessed.  
The study revealed that (a) ACEI exerted the 
expected hypotensive effect and maintained 
renal function (GFR) among the T2DM 
subjects with variable baseline degrees of 
renal insufficiency for that duration of time, 
and (b) ACE ID gene polymorphism had no 
demonstrable influence on the 
antihypertensive effects or the maintenance 




Overall, the use of antihypertensive agents 
(ACE inhibitor alone or with other second-line 
agents) significantly decreased the MAP from 
baseline values. ACEIs had been used as 
first line therapy among these subjects as 
recommended [12]. Only in uncontrolled BP 
situations, second-line agents were added. In 
the present study, aggressive use of 
additional antihypertensive agents were only 
prescribed for patients with MAP ~110 mmHg 
(SBP/DBP, 150/90). In such subjects, the 
dihydropyridine CCBs and diuretics were the 
only types of drugs used as second-line 
antihypertensive agents. These agents are 
well documented for exerting hypotensive 
effects, especially when given in combination 
with ACEI [13]. Similarly in the present study, 
a higher magnitude of change in mean MAP 
was observed among those on ACEI with two 
additional antihypertensive agents indicating 
synergistic drug interaction.  
 
The observed erratic change in MAP 
averages among subjects between clinic 
visits is presumably attributable to poor 
compliance to treatment. Non-compliance 
including failure to replenish prescription, 
consumption of incorrect dose, irregular 
timing, forgetfulness, and premature 
discontinuation of drugs would generally 
prove to be significant impediments to 




Cockcroft-Gault equations were used to 
estimate GFR which, in turn, was used as a 
marker to assess renal function of the 
subjects. Alternatively, the Modified Diet in 
Renal Disease (MDRD) equation may also be 
used for this purpose [15]. Although neither 
serves as an adequate GFR predicting 
formula, cost effectiveness and test 
convenience renders them acceptable for 
short-term studies [16].  Over the 15-month 
duration of the study, GFR was maintained at 
baseline values. The natural course of 
diabetic nephropathy has an average decline 
in GFR of 10 - 15 ml/min/year [1]. Hence, 
AHT regimens including ACEI as 
monotherapy or in combination with 
dihydropyridine CCBs and diuretics, have 
served their purpose by maintaining kidney 
function and preventing further decline in 
GFR.  
 
As this is a retrospective study, it is rather 
difficult to determine the class of 
antihypertensive agents that contributed most 
to GFR maintenance especially when GFR 
trend were similar in all the subgroups 
compared (ACEI vs ACEI+one AHT vs 
ACEI+two AHTs), irrespective of the 
class/number of antihypertensive agents 
used. A critical appraisal of the data suggests 
that there was no significant synergistic anti-
proteinuric effect of dihydropyridine CCBs 
and diuretic type of antihypertensive drugs in 
the present study, unlike other studies that 
reported beneficial renoprotective effect when 
other drugs such as angiotensin II receptor 
antagonist [17] and potassium-sparring 
diuretics [18] were used in combination with 
ACEIs. This implies that ACEI, a common 
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denominator in all the subgroups may have 
been the major contributor to GFR 
maintenance. Although the protective 
influence of ACE inhibition against 
deterioration in renal function is well known 
as it exerts both anti-hypertensive as well as 
anti-proteinuric effects [4,5], the GFR 
maintenance observed in the present study 
may also have been influenced by improved 
blood pressure and glycaemic control among 
the subjects, as HbA1C values at month 15 
were significantly lower than at baseline. A 
prospective observational study had 
previously associated incidences of diabetes 
complications with glycaemic exposure. 
Reduction in haemoglobin A1c by 1 % 
correlated with a decrease
 
in risk for 
microvascular complications and end-point or 
death related to diabetes by 37 and 21 %, 
respectively [19]. Therefore, further validation 
based on a long-term (observational) study 
involving additional judiciously selected 
subgroups (such as a non-ACEI subgroup) 
may be necessary to confirm this assertion.  
 
ACE ID gene polymorphism 
 
Therapeutic outcomes of ACE inhibition were 
previously attributed to polymorphism of the 
ACE gene. DD genotype is associated with 
high-level availability of Ang-II and lower 
availability level of bradykinin in the kidneys, 
causing higher efferent arteriolar resistance 
and intraglomerular pressure while patients 
with ID and II genotype have an intermediate 
and decreased level of vascular and renal 
activity, respectively [6]. Hence, ACE 
inhibition was associated with improved 
survival and renoprotection, with the 
beneficial effects more pronounced in 
subjects with the II and ID genotypes [7]. In 
contrast, Scharplatz et al [20]
 
showed a better 
response to ACE inhibitors in Caucasian DD 
genotype carriers compared to II genotype 
carriers in terms of blood pressure, 
proteinuria, GFR, ACE activity and 
progression to ESRF in a preliminary 
systematic review.  
 
In the present study however, there was no 
apparent impact of ACE ID gene 
polymorphism on the outcomes of 
antihypertensive therapy with regards to MAP 
and GFR in the subjects with diabetic 
nephropathy. The influence of ACE ID gene 
polymorphisms on the treatment outcome 
with ACE inhibitors have previously been 
demonstrated in subjects with type 1 diabetic 
nephropathy [21] and type 2 diabetic 
nephropathy [6,7] and non-diabetic 
nephropathies [22]. Although our finding is in 
contrast to these studies, but it is in 
agreement with reports by van der Kleij et al 
[23] and Schelleman et al [24] in non-diabetic 
renal disease and hypertensive subjects, 
respectively. The authors reported that the 
decline in GFR and blood pressure, in the 
latter study, in response to ACE inhibition 
was not affected by ACE genotype.  
 
Limitations of this study 
 
The observed lack of association between 
genotype and response to ACE inhibition in 
the present study could be due to the 
variation in the pharmacokinetics and 
pharmacodynamics of the type of ACE 
inhibitors [25] prescribed for the subjects. 
Furthermore, the small sample size involved 
in the study made it impossible to assess the 
effects of genotype for the different ACE 
inhibitors separately. In addition, short 
duration of follow-up period [23], as well as 
heterogeneity in ethnicity [26] and gender 
[27] may also have hampered a significant 
association of ACE genotypes. Further 
studies exclusively designed to 
accommodate these pharmacologic and 
demographic factors is deemed necessary to 
confirm our present finding of null influence of 





In this study on Malaysian diabetic subjects, 
ACE ID gene polymorphism had little impact 
on the efficacy of ACE inhibitor therapy with 
regard to MAP and GFR. 
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